CD81 as a tumor target.

CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell-cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform. CD81 has also been shown to regulate cell migration and invasion, and has therefore been implicated in cancer progression. Indeed, we have recently shown that CD81 contributes to tumor growth and metastasis. CD81 is expressed in most types of cancer, including breast, lung, prostate, melanoma, brain cancer and lymphoma, and the overexpression or down-regulation of this molecule has been correlated with either good or bad prognosis. Here, we discuss the role of CD81 in cancer and its potential therapeutic use as a tumor target.

[1]  B. Quesnel,et al.  Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia , 2016, Oncotarget.

[2]  R. Groen,et al.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab , 2015, Leukemia.

[3]  J. Barrett,et al.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.

[4]  D. Maloney,et al.  Rituximab: Mechanism of action and resistance. , 2002, Seminars in oncology.

[5]  R. Cortese,et al.  Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model. , 2015, The Journal of antimicrobial chemotherapy.

[6]  Robert J. Marinelli,et al.  CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. , 2010, Human pathology.

[7]  J. Hyman,et al.  CD63/Pltgp40: a platelet activation antigen identical to the stage-specific, melanoma-associated antigen ME491. , 1991, Blood.

[8]  J. Testa,et al.  The pathogenesis of mesothelioma. , 2002, Seminars in oncology.

[9]  Wun-Jae Kim,et al.  Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray , 2015, PloS one.

[10]  Joel S. Freundlich,et al.  Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein , 2014, PloS one.

[11]  R. Levy,et al.  TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins , 1990, Molecular and cellular biology.

[12]  D. Jeoung,et al.  The Tetraspanin CD81 Protein Increases Melanoma Cell Motility by Up-regulating Metalloproteinase MT1-MMP Expression through the Pro-oncogenic Akt-dependent Sp1 Activation Signaling Pathways* , 2014, The Journal of Biological Chemistry.

[13]  H. Drummer,et al.  Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies , 2014, Front. Microbiol..

[14]  S. Chi,et al.  CD81 is a candidate tumor suppressor gene in human gastric cancer , 2012, Cellular Oncology.

[15]  S. Levy,et al.  Reduced fertility of female mice lacking CD81. , 2006, Developmental biology.

[16]  I. Weissman,et al.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.

[17]  U. Rodeck,et al.  Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[19]  K. Rajewsky,et al.  Isolation of variants of mouse myeloma X63 that express changed immunoglobulin class. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[21]  K. Campbell,et al.  Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81 , 1997, The EMBO journal.

[22]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[23]  M. V. van Zelm,et al.  A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression , 2015, Journal of Clinical Immunology.

[24]  S. Levy,et al.  Normal Lymphocyte Development but Delayed Humoral Immune Response in CD81-null Mice , 1997, The Journal of experimental medicine.

[25]  Rosario Garrido,et al.  Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys , 2013, mAbs.

[26]  M. Terol,et al.  Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients , 2012, Leukemia.

[27]  S. Levy,et al.  Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81 , 2012, Proceedings of the National Academy of Sciences.

[28]  Raymond Liu,et al.  Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin , 2009, Journal of Cell Science.

[29]  V. Carloni,et al.  Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. , 2008, Gastroenterology.

[30]  Scott R Granter,et al.  EWI-2 negatively regulates TGF-β signaling leading to altered melanoma growth and metastasis , 2015, Cell Research.

[31]  B. Barlogie,et al.  Differentiation stage of myeloma plasma cells: biological and clinical significance , 2017, Leukemia.

[32]  Matthew J. Bowman,et al.  Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ‐specific manner , 2013, International journal of cancer.

[33]  S. Levy,et al.  Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. , 2015, Cancer research.

[34]  M. Scharff,et al.  Identification of rare immunoglobulin switch variants using the ELISA spot assay. , 1992, Journal of immunological methods.

[35]  Matthew J. Bowman,et al.  Genetic Ablation of the Tetraspanin CD151 Reduces Spontaneous Metastatic Spread of Prostate Cancer in the TRAMP Model , 2012, Molecular Cancer Research.

[36]  S. Levy,et al.  Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity , 2003, Nature Medicine.

[37]  M. Houghton,et al.  Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. , 2002, Virology.